Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iptacopan in Idiopathic Immune-complex-mediated Membranoproliferative Glomerulonephritis (IC-MPGN)
NCT05755386Phase 3Recruiting
- Sponsor
- Novartis
- Start
- Oct 2023
- Primary completion
- Oct 2028
- Modality
- Small Molecules
- Countries
- 23
01
Overview
A Phase 3 trial of Iptacopan in Idiopathic Immune Complex-Mediated Membranoproliferative Glomerulonephritis (MPGN), sponsored by Novartis. Started Oct 2023; status: recruiting.
02
Drugs
Iptacopan
03
Conditions
Idiopathic Immune Complex-Mediated Membranoproliferative Glomerulonephritis (MPGN)
Beyond the preview
Go deeper on NCT05755386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05755386.